SynthesisFrontiers in oncology2024

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review.

Wenjiao Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.